Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.53 |
| ▸ | ALB | P02768 | 3/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7154210 | 1.00 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14580321 | 1.00 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5821 | 1.00 | LMNA (0.55) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL31662024 | 0.87 | LMNA (0.47) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL8644096 | 0.84 | LMNA (0.45) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1739891 | 0.81 | POLG (0.48) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4285392 | 0.81 | LMNA (0.43) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10510561 | 0.80 | HRAS (0.44) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10512002 | 0.80 | DUT (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL10512094 | 0.78 | NLRP3 (0.44) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2024-08-29 | — | — | US | claimed |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2022-04-14 | — | — | US | claimed |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | CIPLA LIMITED (IN) | 2022-02-01 | — | — | US | claimed |
| US-7205404-B1 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2024-08-29 | — | — | US | disclosed |
| EP-3676252-B1 | DERIVATIVES AND COMPOSITION OF QUINOLINE AND NAPHTHYRIDINE | CHULABHORN FOUND (TH) | 2023-11-29 | — | — | EP | disclosed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115956081-A | Imidazopyridazine compounds having activity as ALK2 inhibitors | 因赛特公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115819417-A | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115835908-A | Bicyclic heterocycles as FGFR inhibitors | 因赛特公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115785090-A | Crystalline forms of FGFR inhibitors and methods of making the same | 因赛特公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2011069688-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-06-16 | — | — | WO | disclosed |
| EP-2223927-A2 | Cyclic phosphonic acid based prodrugs of PMEA and its analogues | Metabasis Therapeutics, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| US-7582748-B2 | efficient synthetic route to an optionally protected 1-halo-2-deoxyribose; formation of an alkyl acetal, such as a methyl acetal, of a furanose, such as 2-deoxyribose, optionally protecting the remaining hydroxyl groups of the furanose, reacting the acetal with an acyl halide that forms the acid halide | MICROBIOLOGICA QUIMICA E FARMACEUTICAL LTD. (BR) | 2009-09-01 | — | — | US | disclosed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1745573-A2 | METHODS OF MANUFACTURE OF 2 -DEOXY-&bgr;-L-NUCLEOSIDES | Microbiologica Quimica E Farmaceutica Ltd. (BR) | 2007-01-24 | — | — | EP | disclosed |
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-12-30 | — | — | US | disclosed |
| WO-2004084453-A2 | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES | MICROBIOLOGICA QUIMICA E FARMACEUTICA LTD. (BR) | 2004-09-30 | — | — | WO | disclosed |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266996-A1 | Methods of manufacture of 2'-deoxy-beta-L-nucleosides | DUT, DAO, DCTD | LMNA 561/4885THRB 2077/4885MTOR 4070/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | LMNA 1694/4885THRB 4870/4885MTOR 1417/4885 |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | PAICS, HAVCR2, THPO | LMNA 3047/4885THRB 1342/4885MTOR 4593/4885 |
| US-20030229225-A1 | Novel phosphonic acid based prodrugs of PMEA and its analogues | MTAP, PNP, MPO | LMNA 2647/4885THRB 2199/4885MTOR 3424/4885 |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | LMNA 3047/4885THRB 1342/4885MTOR 4593/4885 |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | LMNA 3047/4885THRB 1342/4885MTOR 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.